In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin Analog

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Pharmacology and Experimental Therapeutics

• Publication date

  2016-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/jpet.115.231035PMID 27026683
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Long-acting basal insulin].

  2015cited by this paper
• Single‐dose pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 in healthy subjects

  2014influential reference
• Lower Glucose Variability and Hypoglycemia Measured by Continuous Glucose Monitoring With Novel Long-Acting Insulin LY2605541 Versus Insulin Glargine

  2014cited by this paper
• Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus

  2014influential reference
• Contrasting weight changes with LY2605541, a novel long‐acting insulin, and insulin glargine despite similar improved glycaemic control in T1DM and T2DM

  2014cited by this paper
• Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

  2014influential reference
• Hepatoselectivity and the evolution of insulin

  2014cited by this paper
• Novel PEGylated Basal Insulin LY2605541 Has a Preferential Hepatic Effect on Glucose Metabolism

  2014influential reference
• Variability of glucose‐lowering effect as a limiting factor in optimizing basal insulin therapy: a review

  2013cited by this paper
• Better Glycemic Control and Weight Loss With the Novel Long-Acting Basal Insulin LY2605541 Compared With Insulin Glargine in Type 1 Diabetes

  2013influential reference
• Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

  2012cited by this paper
• Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin

  2012cited by this paper
• Molecular Characterisation of Long-Acting Insulin Analogues in Comparison with Human Insulin, IGF-1 and Insulin X10

  2012influential reference
• A Randomized, Controlled Study of Once-Daily LY2605541, a Novel Long-Acting Basal Insulin, Versus Insulin Glargine in Basal Insulin–Treated Patients With Type 2 Diabetes

  2012cited by this paper
• Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

  2012cited by this paper
• Comment on: Soranzo et al. Common Variants at 10 Genomic Loci Influence Hemoglobin A1C Levels via Glycemic and Nonglycemic Pathways. Diabetes 2010;59:3229–3239

  2011cited by this paper
• Insulin X10 revisited: a super-mitogenic insulin analogue

  2011cited by this paper
• Factors Associated with Persistence and Resumption of Insulin Pen Use for Patients with Type 2 Diabetes

  2011cited by this paper
• Optimizing the Replacement of Basal Insulin in Type 1 Diabetes Mellitus: No Longer an Elusive Goal in the Post-NPH Era

  2011cited by this paper
• Insulin detemir is a fully efficacious, low affinity agonist at the insulin receptor

  2010cited by this paper
• Improved Glycemic Control With Intraperitoneal Versus Subcutaneous Insulin in Type 1 Diabetes

  2009cited by this paper
• Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes: a Double-Blind, Randomized, Crossover Study

  2008cited by this paper
• Mitogenic Effect of the Insulin Analogue Glargine in Malignant Cells in Comparison with Insulin and IGF-I

  2008cited by this paper
• Comparison of Pharmacokinetics and Dynamics of the Long-Acting Insulin Analogs Glargine and Detemir at Steady State in Type 1 Diabetes

  2007cited by this paper
• pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity.

  2007cited by this paper
• Comparison of the effects on glucose and lipid metabolism of equipotent doses of insulin detemir and NPH insulin with a 16-h euglycaemic clamp

  2005cited by this paper
• The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

  2004cited by this paper
• Insulin glargine: a systematic review of a long-acting insulin analogue.

  2003cited by this paper
• Lymphatic Absorption Is a Significant Contributor to the Subcutaneous Bioavailability of Insulin in a Sheep Model

  2001cited by this paper
• Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans.

  2000influential reference
• Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

  2000cited by this paper
• Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use.

  2000influential reference
• Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency.

  1996cited by this paper
• Antigen-antibody interaction. Synthetic peptides define linear antigenic determinants recognized by monoclonal antibodies directed to the cytoplasmic carboxyl terminus of rhodopsin.

  1988cited by this paper
• Expression of a synthetic bovine rhodopsin gene in monkey kidney cells.

  1987cited by this paper
• Kinetics of circulating endogenous insulin, C-peptide, and proinsulin in fasting nondiabetic man.

  1987cited by this paper
• Landmark article Jan 18, 1936: Protamine insulinate. By H.C. Hagedorn, B.N. Jensen, N.B. Krarup, and I. Wodstrup.

  1984cited by this paper
• Splanchnic and renal metabolism of insulin in human subjects: a dose-response study.

  1983cited by this paper
• Impaired in Vivo Insulin Clearance in Patients With Severe Target-Cell Resistance to Insulin

  1982cited by this paper
• Insulin production rate following glucose ingestion estimated by splanchnic C-peptide output in normal man

  1979influential reference
• Effect of renal disease on renal uptake and excretion of insulin in man.

  1970cited by this paper
• The lente insulins.

  1956cited by this paper
• The Lente Insulins

  1956cited by this paper
• Protamine Insulinate

  1937cited by this paper

• The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa

  2024influential citation
• Preclinical Characterization of LY3209590, a Novel Weekly Basal Insulin Fc-Fusion Protein

  2022influential citation
• Comprehensive insulin receptor phosphorylation dynamics profiled by mass spectrometry

  2021cites this paper
• Affinity-Directed Dynamics of Host-Guest Motifs for Pharmacokinetic Modulation via Supramolecular PEGylation.

  2021cites this paper
• Engineering biopharmaceutical formulations to improve diabetes management

  2021cites this paper
• Facile synthesis of insulin fusion derivatives through sortase A ligation

  2020cites this paper
• Glycosaminoglycan-Conjugated Insulin Derivatives Suitable for Once-Daily Formulations

  2019cites this paper
• Insulin-like Peptide 5 Fails to Improve Metabolism or Body Weight in Obese Mice.

  2019cites this paper
• Nonclinical pharmacology and toxicology of the first biosimilar insulin glargine drug product (BASAGLAR®/ABASAGLAR®) approved in the European Union

  2017cites this paper
• Quantification of Basal Insulin Peglispro and Human Insulin in Adipose Tissue Interstitial Fluid by Open-Flow Microperfusion

  2017cites this paper
• Hypoglycemia Risk Related to Double Dose Is Markedly Reduced with Basal Insulin Peglispro Versus Insulin Glargine in Patients with Type 2 Diabetes Mellitus in a Randomized Trial: IMAGINE 8

  2017cites this paper
• Internalization and localization of basal insulin peglispro in cells.

  2017cites this paper
• Addition of 20-kDa PEG to Insulin Lispro Alters Absorption and Decreases Clearance in Animals

  2016cites this paper
• Hepato‐preferential insulins: Is this the end, or the end of the beginning?

  2016cites this paper
• Reduced peripheral activity leading to hepato‐preferential action of basal insulin peglispro compared with insulin glargine in patients with type 1 diabetes

  2016cites this paper
• Science Journals — AAAS

  2016cites this paper
• Basal insulin peglispro: Overview of a novel long‐acting insulin with reduced peripheral effect resulting in a hepato‐preferential action

  2016cites this paper